Table 2.
Hb-HDACIs in the clinic.
| HDACIs | Routes of administration | Side effects | FDA approval |
|---|---|---|---|
| Vorinostat | Oral | Anorexia, fatigue, dehydration, diarrhea, and myelosuppression | Cutaneous T-cell lymphoma |
| Belinostat (PXD101) | Oral, i.v. | Lethargy/fatigue, nausea and vomiting | Granted orphan drug and fast track designations for relapsed or refractory peripheral T-cell lymphoma |
| Panobinostat (LBH589) | Oral, i.v | Fatigue, nausea, diarrhea and myelosuppression | Not approved |
| Pracinostat (SB939) | Oral | Fatigue, nausea, vomiting, anorexia and diarrhoea | Not approved |
| Abexinostat (PCI-24781/ CRA-024781) | Oral, i.v. | Under evaluation in clinical trials | Not approved |
| JNJ-26481585 | Oral | Under evaluation in clinical trials | Not approved |
| Dacinostat (LAQ824) | i.v. | Nausea, vomiting and fatigue | Not approved |
| Resminostat (RAS2410/4SC-201) | Oral | Under evaluation in clinical trials | Granted orphan drug designation in relapsed/refractory Hodgkin’s lymphoma and hepatocellular carcinoma |
| CHR-3996 | Oral | Thrombocytopenia, fatigue, increase of plasma creatinine and atrial fibrillation | Not approved |
Abbreviations: FDA, United States Food and Drug Administration; i.v., intravenous.